Camp4 Registers Resale of 32.7M Shares from $50.1M Private Placement, Representing 38.6% of Outstanding

summarizeSummary

Camp4 Therapeutics registered the resale of 32.7 million shares from its recent $50.1 million private placement, creating a significant tradable overhang equal to 38.6% of outstanding shares.

check_boxKey Events · Financing and Capital Events · CAMP

• Resale Registration Filed

  An S-3 was filed to register the resale of 10,795,804 common shares and 21,925,368 shares underlying pre-funded warrants, all issued in the August 3, 2026 second closing of the private placement.

• Significant Overhang Created

  Assuming exercise of the pre-funded warrants, the registered shares represent approximately 38.6% of total outstanding common stock as of August 3, 2026, creating a large potential supply overhang.

• Follows Recent $50.1M Financing

  The registration covers shares from the second closing of a private placement that raised $50.1 million in gross proceeds, with shares sold at $1.53–$1.65 per share—well below the current $4.50 stock price.

• No Proceeds to Company

  Camp4 will not receive any proceeds from the resale of these shares; it may receive nominal proceeds if pre-funded warrants are exercised for cash at $0.0001 per share.

auto_awesomeAnalysis · CAMP · Life Sciences

Just three days after the second closing of its private placement, Camp4 filed an S-3 to register the resale of 32.7 million shares—10.8 million common shares and 21.9 million shares underlying pre-funded warrants. That block represents approximately 38.6% of the company's outstanding common stock. While the $50.1 million raised extends the cash runway for lead program CMP-002, making this overhang immediately tradable could pressure the stock. The filing fulfills a contractual obligation under the September 2025 registration rights agreement.